Josh's Shared Resources
Pandemic Disrupts LAI Antipsychotic Use in Schizophrenia Care
In 2020, the Sars-CoV-2 pandemic emerged as a significant global health crisis, with more than six million fatalities and nearly...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Survey Shows Clinician Hesitancy, Training Gaps in Long-Acting Injectables for Schizophrenia
This study assessed the use, attitudes, and obstacles regarding long-acting injectable (LAI) antipsychotic medications among U.S. psychiatric clinicians treating schizophrenia....
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Unlocking Social Cognition in Schizophrenia: Insights and Challenges
Social cognition is severely impaired in schizophrenia, leading to challenges in relationships and employment. Despite its critical role, understanding the...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Unraveling the Complexity of Schizophrenia: Insights from Genetics, Neuroimaging, and Neurobiology
Schizophrenia is a complex, chronic mental disorder marked by symptoms such as hallucinations, delusions, social withdrawal, and emotional flatness. Diagnosis...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Meta-Analysis Shows Major Cognitive Deficits in Treatment-Resistant Schizophrenia
Treatment-resistant schizophrenia (TRS) impacts roughly one-third of individuals diagnosed with schizophrenia, with 70-84% demonstrating resistance to treatment from the onset....
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Maintenance Electroconvulsive Therapy Proves Effective for Treatment-Resistant Schizophrenia
A recent study aimed to evaluate the efficacy and safety of maintenance electroconvulsive therapy (M-ECT) in patients with treatment-resistant schizophrenia...
Josh Hamilton,
DNP, APRN-BC, CTMH, CNE, CLNC, FAANP
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC
Chief Clinical Officer, The Hamilton Group Behavioral Health LLC